CelLBxHealth plc (AIM:CLBX)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 19.60M -21.6% |
| Revenue (ttm) | 2.62M +29.6% |
| Net Income | -15.78M |
| EPS | -0.05 |
| Shares Out | 1.14B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,870,565 |
| Open | 1.739 |
| Previous Close | 1.725 |
| Day's Range | 1.688 - 1.800 |
| 52-Week Range | 0.850 - 11.000 |
| Beta | 0.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 1, 2026 |
About CelLBxHealth
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytic... [Read more]
Financial Performance
In 2024, CelLBxHealth's revenue was 2.86 million, an increase of 30.92% compared to the previous year's 2.19 million. Losses were -14.23 million, -29.34% less than in 2023.
Financial StatementsNews
CelLBxHealth Earnings release: Q4 2025
CelLBxHealth released its Q4 2025 earnings on January 16, 2026, summarizing the period's financial results.
CelLBxHealth Transcript: Investor Update
A new leadership team is driving a focused commercialization strategy, restructuring operations, and targeting profitability by 2028. Strategic partnerships and a narrowed market focus aim to capitalize on the growing need for circulating tumor cell diagnostics, with significant cost reductions and value inflection points expected in the next 12-18 months.
CelLBxHealth Slides: Investor Update
CelLBxHealth has posted slides in relation to its latest quarterly earnings report, which was published on November 26, 2025.
CelLBxHealth Earnings Call Transcript: H1 2025
Major commercialization progress with pharma and medtech, including a new Myriad Genetics partnership, was offset by revenue declines due to market headwinds. Cost controls reduced losses, and the cash runway extends into Q1 2026. NHS engagement and new clinical evidence support future growth.
CelLBxHealth Quarterly report: H1 2025
CelLBxHealth has published its H1 2025 quarterly earnings report on September 9, 2025.
CelLBxHealth Slides: H1 2025
CelLBxHealth has posted slides in relation to its H1 2025 quarterly earnings report, which was published on September 9, 2025.
CelLBxHealth Earnings Call Transcript: H2 2024
2024 saw 31% revenue growth, major pharma contracts, and a breakthrough in DNA dual analysis, despite market headwinds and funding delays. The pipeline is strong, with new medtech and pharma opportunities, and a cash runway into Q1 2026.
CelLBxHealth Annual report: H2 2024
CelLBxHealth has published its H2 2024 annual report on May 28, 2025.
CelLBxHealth Annual report: H2 2024
CelLBxHealth has published its H2 2024 annual report on May 28, 2025.
CelLBxHealth Slides: H2 2024
CelLBxHealth has posted slides in relation to its H2 2024 quarterly earnings report, which was published on May 28, 2025.
Angle PLC Announces Parsortix study uncovers targets in TNBC patients
Parsortix system harvests intact CTCs for whole genomic sequencing identifying multiple druggable targets Study demonstrates ctDNA and CTCs can both be analysed using the same blood sample GUILDFORD, ...